Immediate clinical applications of these findings include a planned clinical trial to treat HLA-A*0101+/VGLL1+ PDAC patients with VGLL1-specific ETC therapy, with future cohorts to potentially include bladder, ovarian, and/or breast cancer patients. Here, VGLL1 is linked to breast carcinoma.